BofA lifts gold target to $5,000/oz, sees silver staying in deficit
Lilly Endowment Inc. sold 10,522 shares of Eli Lilly & Co (NYSE:LLY) common stock on October 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales, executed in multiple transactions, fetched prices ranging from $848.63 to $857.255, resulting in a total value of $9,038,055.
The transactions decreased Lilly Endowment’s direct ownership in Eli Lilly to 94,536,978 shares.
In other recent news, Eli Lilly has seen significant developments that may interest investors. Guggenheim has raised its price target for Eli Lilly to $948, maintaining a Buy rating, and forecasts third-quarter Mounjaro sales to reach $5.49 billion, slightly surpassing consensus estimates. Meanwhile, TD Cowen has reiterated its Buy rating with a price target of $960, highlighting Eli Lilly’s strong growth prospects and consistent innovation. Additionally, Eli Lilly announced that its ulcerative colitis treatment, Omvoh, has shown sustained efficacy over four years, with 80% of patients maintaining clinical remission. Guggenheim also reiterated its Buy rating with a maintained price target of $875, noting strong growth expectations for 2025 and stable margins. These updates underscore the company’s ongoing efforts and potential in the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.